Company Profile
Catalyst Biosciences Stock Price, News & Analysis
- Ticker:
- CBIO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
16.93 USD (+3.87%)
Close
Last updated: July 27, 2026
469M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, CBIO closed up 3.87% at $16.93. No new same-company headline was identified in the current news window.
Company overview
Business overview
Catalyst Biosciences was a biotechnology company focused on engineered proteins for hemostasis, complement, and related inflammatory biology before becoming a historical ticker. Its story was built around protein-engineering approaches to difficult disease pathways.
Geographic Base and Sector Classification
Catalyst Biosciences was headquartered in the United States and listed on NASDAQ. It sat in specialty biotech with a protein-engineering focus.
Business Model Characteristics
The company depended on translational data, strategic direction, and financing while working through a narrow pipeline. Investors historically watched whether the platform could create durable value across multiple programs.
Position Within the Biotechnology Landscape
Catalyst Biosciences belongs to the historical engineered-protein biotech bucket. Its stock was highly sensitive to strategic changes and the viability of its platform thesis.
Future catalysts
Catalyst Biosciences is largely a legacy / closeout story, with catalysts limited to any remaining strategic update. There is no active standalone growth story left.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
- 02
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Source: Catalyst Biosciences
- 03
- 04
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Source: Catalyst Biosciences
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Catalyst Biosciences (CBIO)?
Catalyst Biosciences (CBIO) most recently closed at 16.93 USD, a +3.87% move versus the previous session.
What is the market cap of Catalyst Biosciences (CBIO)?
Catalyst Biosciences currently has a market capitalization of 469M USD on BioPharmSignal.
What does Catalyst Biosciences do?
Catalyst Biosciences was a biotechnology company focused on engineered proteins for hemostasis, complement, and related inflammatory biology before becoming a historical ticker. Its story was built around protein-engineering approaches to difficult disease pathways.
On which exchange is CBIO stock listed?
Catalyst Biosciences (CBIO) is associated with NASDAQ, United States, Biopharma.
What is Catalyst?
Catalyst Biosciences is largely a legacy / closeout story, with catalysts limited to any remaining strategic update.
Which conditions is Catalyst Biosciences targeting with Catalyst?
Catalyst Biosciences is largely a legacy / closeout story, with catalysts limited to any remaining strategic update.
How does Catalyst Biosciences describe recent progress with Catalyst?
Catalyst Biosciences is largely a legacy / closeout story, with catalysts limited to any remaining strategic update.
What is Biosciences?
Catalyst Biosciences was a biotechnology company focused on engineered proteins for hemostasis, complement, and related inflammatory biology before becoming a historical ticker.